Time evolution of DOTATOC uptake in neuroendocrine tumors in view of a possible application of radioguided surgery with b2 decay

Francesco Collamati, Fabio Bellini, Valerio Bocci, Erika De Lucia, Valentina Ferri, Federica Fioroni, Elisa Grassi, Mauro Iori, Michela Marafini, Silvio Morganti, Riccardo Paramatti, Vincenzo Patera, Luigi Recchia, Andrea Russomando, Alessio Sarti, Adalberto Sciubba, Martina Senzacqua, Elena Solfaroli Camillocci, Annibale Versari, Cecilia VoenaRiccardo Faccini

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

A novel radioguided surgery (RGS) technique exploiting β. radiation has been proposed. To develop such a technique, a suitable radiotracer able to deliver a β. emitter to the tumor has to be identified. A first candidate is represented by 90Y-labeled DOTATOC, a compound commonly used today for peptide radioreceptor therapy. The application of this β. RGS to neuroendocrine tumors (NET) requires study of the uptake of DOTATOC and its time evolution both in tumors and in healthy organs and evaluation of the corresponding performance of the technique. Methods: Uptake by lesions and healthy organs (kidneys, spleen, liver and healthy muscle) was estimated on 177Lu-DOTATOC SPECT/CT scans of 15 patients affected by NET with different localizations, treated at IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy. For each patient, SPECT/CT images, acquired at 0.5, 4, 20, 40, and 70 h after injection, were studied. For each lesion, the tumor-tonontumor ratio (TNR) with respect to all healthy organs and its time evolution were studied. A subset of patients showing hepatic lesions was selected, and the TNR with respect to the nearby healthy tissue was calculated. By means of a Monte Carlo simulation of the probe for β. RGS, the activity that is to be administered for a successful detection was estimated lesion-by-lesion. Results: Uptake of DOTATOC on NETs maximized at about 24 h after injection. The cases of hepatic lesions showed a TNR with respect to the tumor margins compatible with the application of β. RGS. In particular, 0.1-mL residuals are expected to be detectable within 1 s with 5% false-negative and 1% false-positive by administering the patient as little as 1 MBq/kg. Conclusion: The balance between tumor uptake and metabolic washout in healthy tissue causes the TNR to increase with time, reaching its maximum after 24 h, and this characteristic can be exploited when a radiotracer with a long halflife, such as 90Y, is used. In particular, if 90Y-DOTATOC is used with liver NET metastases, the proposed RGS technique is believed to be feasible by injecting an activity that is one third of that commonly used for PET imaging.

Original languageEnglish
Pages (from-to)1501-1506
Number of pages6
JournalJournal of Nuclear Medicine
Volume56
Issue number10
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

Neuroendocrine Tumors
Liver
Neoplasms
Injections
Italy
Half-Life
Spleen
Edotreotide
Radiation
Neoplasm Metastasis
Kidney
Muscles
Peptides

Keywords

  • DOTATOC uptake
  • Neuroendocrine tumors
  • Radioguided surgery
  • βradiation

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Time evolution of DOTATOC uptake in neuroendocrine tumors in view of a possible application of radioguided surgery with b2 decay. / Collamati, Francesco; Bellini, Fabio; Bocci, Valerio; De Lucia, Erika; Ferri, Valentina; Fioroni, Federica; Grassi, Elisa; Iori, Mauro; Marafini, Michela; Morganti, Silvio; Paramatti, Riccardo; Patera, Vincenzo; Recchia, Luigi; Russomando, Andrea; Sarti, Alessio; Sciubba, Adalberto; Senzacqua, Martina; Camillocci, Elena Solfaroli; Versari, Annibale; Voena, Cecilia; Faccini, Riccardo.

In: Journal of Nuclear Medicine, Vol. 56, No. 10, 01.10.2015, p. 1501-1506.

Research output: Contribution to journalArticle

Collamati, F, Bellini, F, Bocci, V, De Lucia, E, Ferri, V, Fioroni, F, Grassi, E, Iori, M, Marafini, M, Morganti, S, Paramatti, R, Patera, V, Recchia, L, Russomando, A, Sarti, A, Sciubba, A, Senzacqua, M, Camillocci, ES, Versari, A, Voena, C & Faccini, R 2015, 'Time evolution of DOTATOC uptake in neuroendocrine tumors in view of a possible application of radioguided surgery with b2 decay', Journal of Nuclear Medicine, vol. 56, no. 10, pp. 1501-1506. https://doi.org/10.2967/jnumed.115.160481
Collamati, Francesco ; Bellini, Fabio ; Bocci, Valerio ; De Lucia, Erika ; Ferri, Valentina ; Fioroni, Federica ; Grassi, Elisa ; Iori, Mauro ; Marafini, Michela ; Morganti, Silvio ; Paramatti, Riccardo ; Patera, Vincenzo ; Recchia, Luigi ; Russomando, Andrea ; Sarti, Alessio ; Sciubba, Adalberto ; Senzacqua, Martina ; Camillocci, Elena Solfaroli ; Versari, Annibale ; Voena, Cecilia ; Faccini, Riccardo. / Time evolution of DOTATOC uptake in neuroendocrine tumors in view of a possible application of radioguided surgery with b2 decay. In: Journal of Nuclear Medicine. 2015 ; Vol. 56, No. 10. pp. 1501-1506.
@article{c67818638b2a424e9c405bbf15a6a2df,
title = "Time evolution of DOTATOC uptake in neuroendocrine tumors in view of a possible application of radioguided surgery with b2 decay",
abstract = "A novel radioguided surgery (RGS) technique exploiting β. radiation has been proposed. To develop such a technique, a suitable radiotracer able to deliver a β. emitter to the tumor has to be identified. A first candidate is represented by 90Y-labeled DOTATOC, a compound commonly used today for peptide radioreceptor therapy. The application of this β. RGS to neuroendocrine tumors (NET) requires study of the uptake of DOTATOC and its time evolution both in tumors and in healthy organs and evaluation of the corresponding performance of the technique. Methods: Uptake by lesions and healthy organs (kidneys, spleen, liver and healthy muscle) was estimated on 177Lu-DOTATOC SPECT/CT scans of 15 patients affected by NET with different localizations, treated at IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy. For each patient, SPECT/CT images, acquired at 0.5, 4, 20, 40, and 70 h after injection, were studied. For each lesion, the tumor-tonontumor ratio (TNR) with respect to all healthy organs and its time evolution were studied. A subset of patients showing hepatic lesions was selected, and the TNR with respect to the nearby healthy tissue was calculated. By means of a Monte Carlo simulation of the probe for β. RGS, the activity that is to be administered for a successful detection was estimated lesion-by-lesion. Results: Uptake of DOTATOC on NETs maximized at about 24 h after injection. The cases of hepatic lesions showed a TNR with respect to the tumor margins compatible with the application of β. RGS. In particular, 0.1-mL residuals are expected to be detectable within 1 s with 5{\%} false-negative and 1{\%} false-positive by administering the patient as little as 1 MBq/kg. Conclusion: The balance between tumor uptake and metabolic washout in healthy tissue causes the TNR to increase with time, reaching its maximum after 24 h, and this characteristic can be exploited when a radiotracer with a long halflife, such as 90Y, is used. In particular, if 90Y-DOTATOC is used with liver NET metastases, the proposed RGS technique is believed to be feasible by injecting an activity that is one third of that commonly used for PET imaging.",
keywords = "DOTATOC uptake, Neuroendocrine tumors, Radioguided surgery, βradiation",
author = "Francesco Collamati and Fabio Bellini and Valerio Bocci and {De Lucia}, Erika and Valentina Ferri and Federica Fioroni and Elisa Grassi and Mauro Iori and Michela Marafini and Silvio Morganti and Riccardo Paramatti and Vincenzo Patera and Luigi Recchia and Andrea Russomando and Alessio Sarti and Adalberto Sciubba and Martina Senzacqua and Camillocci, {Elena Solfaroli} and Annibale Versari and Cecilia Voena and Riccardo Faccini",
year = "2015",
month = "10",
day = "1",
doi = "10.2967/jnumed.115.160481",
language = "English",
volume = "56",
pages = "1501--1506",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "10",

}

TY - JOUR

T1 - Time evolution of DOTATOC uptake in neuroendocrine tumors in view of a possible application of radioguided surgery with b2 decay

AU - Collamati, Francesco

AU - Bellini, Fabio

AU - Bocci, Valerio

AU - De Lucia, Erika

AU - Ferri, Valentina

AU - Fioroni, Federica

AU - Grassi, Elisa

AU - Iori, Mauro

AU - Marafini, Michela

AU - Morganti, Silvio

AU - Paramatti, Riccardo

AU - Patera, Vincenzo

AU - Recchia, Luigi

AU - Russomando, Andrea

AU - Sarti, Alessio

AU - Sciubba, Adalberto

AU - Senzacqua, Martina

AU - Camillocci, Elena Solfaroli

AU - Versari, Annibale

AU - Voena, Cecilia

AU - Faccini, Riccardo

PY - 2015/10/1

Y1 - 2015/10/1

N2 - A novel radioguided surgery (RGS) technique exploiting β. radiation has been proposed. To develop such a technique, a suitable radiotracer able to deliver a β. emitter to the tumor has to be identified. A first candidate is represented by 90Y-labeled DOTATOC, a compound commonly used today for peptide radioreceptor therapy. The application of this β. RGS to neuroendocrine tumors (NET) requires study of the uptake of DOTATOC and its time evolution both in tumors and in healthy organs and evaluation of the corresponding performance of the technique. Methods: Uptake by lesions and healthy organs (kidneys, spleen, liver and healthy muscle) was estimated on 177Lu-DOTATOC SPECT/CT scans of 15 patients affected by NET with different localizations, treated at IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy. For each patient, SPECT/CT images, acquired at 0.5, 4, 20, 40, and 70 h after injection, were studied. For each lesion, the tumor-tonontumor ratio (TNR) with respect to all healthy organs and its time evolution were studied. A subset of patients showing hepatic lesions was selected, and the TNR with respect to the nearby healthy tissue was calculated. By means of a Monte Carlo simulation of the probe for β. RGS, the activity that is to be administered for a successful detection was estimated lesion-by-lesion. Results: Uptake of DOTATOC on NETs maximized at about 24 h after injection. The cases of hepatic lesions showed a TNR with respect to the tumor margins compatible with the application of β. RGS. In particular, 0.1-mL residuals are expected to be detectable within 1 s with 5% false-negative and 1% false-positive by administering the patient as little as 1 MBq/kg. Conclusion: The balance between tumor uptake and metabolic washout in healthy tissue causes the TNR to increase with time, reaching its maximum after 24 h, and this characteristic can be exploited when a radiotracer with a long halflife, such as 90Y, is used. In particular, if 90Y-DOTATOC is used with liver NET metastases, the proposed RGS technique is believed to be feasible by injecting an activity that is one third of that commonly used for PET imaging.

AB - A novel radioguided surgery (RGS) technique exploiting β. radiation has been proposed. To develop such a technique, a suitable radiotracer able to deliver a β. emitter to the tumor has to be identified. A first candidate is represented by 90Y-labeled DOTATOC, a compound commonly used today for peptide radioreceptor therapy. The application of this β. RGS to neuroendocrine tumors (NET) requires study of the uptake of DOTATOC and its time evolution both in tumors and in healthy organs and evaluation of the corresponding performance of the technique. Methods: Uptake by lesions and healthy organs (kidneys, spleen, liver and healthy muscle) was estimated on 177Lu-DOTATOC SPECT/CT scans of 15 patients affected by NET with different localizations, treated at IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy. For each patient, SPECT/CT images, acquired at 0.5, 4, 20, 40, and 70 h after injection, were studied. For each lesion, the tumor-tonontumor ratio (TNR) with respect to all healthy organs and its time evolution were studied. A subset of patients showing hepatic lesions was selected, and the TNR with respect to the nearby healthy tissue was calculated. By means of a Monte Carlo simulation of the probe for β. RGS, the activity that is to be administered for a successful detection was estimated lesion-by-lesion. Results: Uptake of DOTATOC on NETs maximized at about 24 h after injection. The cases of hepatic lesions showed a TNR with respect to the tumor margins compatible with the application of β. RGS. In particular, 0.1-mL residuals are expected to be detectable within 1 s with 5% false-negative and 1% false-positive by administering the patient as little as 1 MBq/kg. Conclusion: The balance between tumor uptake and metabolic washout in healthy tissue causes the TNR to increase with time, reaching its maximum after 24 h, and this characteristic can be exploited when a radiotracer with a long halflife, such as 90Y, is used. In particular, if 90Y-DOTATOC is used with liver NET metastases, the proposed RGS technique is believed to be feasible by injecting an activity that is one third of that commonly used for PET imaging.

KW - DOTATOC uptake

KW - Neuroendocrine tumors

KW - Radioguided surgery

KW - βradiation

UR - http://www.scopus.com/inward/record.url?scp=84943157334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943157334&partnerID=8YFLogxK

U2 - 10.2967/jnumed.115.160481

DO - 10.2967/jnumed.115.160481

M3 - Article

C2 - 26338895

AN - SCOPUS:84943157334

VL - 56

SP - 1501

EP - 1506

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 10

ER -